SCHEMBL13675679

SCHEMBL13675679

O=C(C=C(c1ccc(Br)cc1)c1ccc(Br)cc1)Nc1ccc2c(c1)OCCO2

nearest known ligand 0.72

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 8/20 0.72
NPC1 O15118 8/20 0.70
RAB9A P51151 8/20 0.70
MAOB P27338 1/20 0.62
MEN1 O00255 3/20 0.58
KMT2A Q03164 3/20 0.58
GAA P10253 1/20 0.58
ALDH1A1 P00352 2/20 0.55
SMN1; SMN2 Q16637 3/20 0.53
TP53 P04637 2/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
CYP1A2 P05177 1/20 0.52
CYP2C19 P33261 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
CASP3 P42574 1/20 0.52
SENP7 Q9BQF6 1/20 0.52
POLB P06746 1/20 0.52
MAPT P10636 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14566136 0.94 TRPV1 (0.65) TRPV1NPC1RAB9AMAOBMEN1
SCHEMBL4002352 0.87 TRPV1 (0.76) TRPV1NPC1RAB9AMEN1KMT2A
SCHEMBL13675680 0.84 TRPV1 (1.00) TRPV1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL5171565 0.82 RAB9A (1.00) NPC1RAB9AMAOBMEN1KMT2A
SCHEMBL13675707 0.80 TRPV1 (0.91) TRPV1NPC1RAB9AMEN1KMT2A
SCHEMBL3998011 0.80 TRPV1 (1.00) TRPV1NPC1RAB9AMEN1KMT2A
SCHEMBL3998005 0.80 TRPV1 (1.00) TRPV1NPC1RAB9AMEN1KMT2A
SCHEMBL13675900 0.80 TRPV1 (1.00) TRPV1NPC1RAB9AMEN1KMT2A
SCHEMBL13675708 0.79 TRPV1 (0.89) TRPV1NPC1RAB9AMAOBMEN1
SCHEMBL13675709 0.79 TRPV1 (0.89) TRPV1RAB9AMAOBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264424-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS AMGEN INC. 2009-10-22 US disclosed
US-20090264424-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS AMGEN INC. 2009-10-22 US disclosed
US-7582657-B2 Treating inflammatory and neuropathic pain, headache, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, eye disorders, bladder disorders, psoriasis, skin disorders, asthma, herpes simplex AMGEN INC. (US) 2009-09-01 US disclosed
US-7582657-B2 Treating inflammatory and neuropathic pain, headache, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, eye disorders, bladder disorders, psoriasis, skin disorders, asthma, herpes simplex AMGEN INC. (US) 2009-09-01 US disclosed
US-7579347-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2009-08-25 US disclosed
US-7579347-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2009-08-25 US disclosed
EP-1780196-A2 Pyridine derivatives for use as vanilloid receptor ligands Amgen, Inc (US) 2007-05-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264424-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS TRPV1, TRPV2, TRPV3 TRPV1 1/4885NPC1 2982/4885RAB9A 1356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.